Gotowa bibliografia na temat „United States. National Advisory Committee on Education”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „United States. National Advisory Committee on Education”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "United States. National Advisory Committee on Education"
1
Glidden, Peter L. "Soundoff: How National Examinations Can Benefit Students and Teachers". Mathematics Teacher 85, nr 8 (listopad 1992): 610–11. http://dx.doi.org/10.5951/mt.85.8.0610.
Pełny tekst źródłaStreszczenie:
Several reform groups, including the President's Education Policy Advisory Committee and Educate America, are calling for national examinations for high school students. Examination advocates claim the following benefits: the establishment of national standards, increased accountability, and increased motivation for students. Advocates also point out that the United States is the only major industrialized country without some sort of national examination. Critics claim that examinations restrict teachers' creativity; force teachers to teach for the examination; and promote improper comparisons among states, districts, schools, teachers, and students. (See, e.g., DeWitt [1991]).
2
Duncan, Pamela W. "One Grip a Little Stronger". Physical Therapy 83, nr 11 (1.11.2003): 1014–21. http://dx.doi.org/10.1093/ptj/83.11.1014.
Pełny tekst źródłaStreszczenie:
Abstract Pamela W Duncan, PT, PhD, FAPTA Dr Duncan has actively participated in and contributed to physical therapist practice, physical therapist professional education, professional preparation of other health care providers, national policy development related to rehabilitation after stroke and aging, and scientific investigation. She has served several government appointments and provides leadership within several organizations. She served as co-chair of the Consensus Panel on Establishing Guidelines for Stroke Rehabilitation for the Agency for Health Care Policy, Research, and Education. She was a panel member on the National Institutes of Health's Total Hip Replacement Consensus Conference and served on the Strategic Planning Group for Stroke Research for the National Institute of Neurological Disorders and Stroke. She recently was appointed to serve on the Steering Committee of the Department of Education's National Institute on Disability and Rehabilitation Research and is currently on the Executive Leadership Council of the American Stroke Foundation and the Advisory Committee of the Canadian Stroke Network. She has served on committees and panels for the American Heart Association and was president of APTA's Neurology section. Dr Duncan's research activities focus on geriatric rehabilitation, stroke rehabilitation, and health outcomes measurement. She developed the Functional Reach Test, used to assess balance in older adults. In the past 20 years, she has received $13 million in research awards as principal investigator or co-investigator from agencies such as the National Institutes of Health, National Institute on Aging, American Heart Association, Department of Veteran's Affairs, and National Center for Medical Rehabilitation Research and from multiple private funding sources. Dr Duncan has disseminated her research findings in more than 80 peer-reviewed articles in 20 different journals, and she has written a book and 12 book chapters. Dr Duncan's work has influenced the care and rehabilitation of patients in the United States and worldwide. Physical therapy education programs across the country incorporate her findings and professional vision into the preparation of the next generation of physical therapists. APTA has awarded Dr Duncan the Marian Williams Award for Research in Physical Therapy, the Catherine Worthingham Fellowship Award, and the Mary McMillan Scholarship Award. She has also received research awards from the APTA Neurology Section, Sports Physical Therapy Section, and Section on Geriatrics, as well as a service award from the Neurology Section. She is an elected fellow of the Stroke Council of the American Heart Association and has given 8 invited lectureships at universities across the United States.
3
Harris, Lauren, Daniel Gilmore, Anne Longo i Brittany N. Hand. "Short report: Patterns of US federal autism research funding during 2017–2019". Autism 25, nr 7 (25.03.2021): 2135–39. http://dx.doi.org/10.1177/13623613211003430.
Pełny tekst źródłaStreszczenie:
In 2017, the Interagency Autism Coordinating Committee, a federal advisory panel consisting of autism researchers and community members, recommended that funders of autism research prioritize research projects on: (1) treatments/interventions, (2) evidence-based services, and (3) lifespan issues. We sought to describe research funding since this recommendation was made. We searched the databases of the three largest federal funders of autism research in the United States (National Institutes of Health, Department of Education, and Centers for Disease Control and Prevention) for grants awarded during 2017–2019. We categorized grants as follows: autism screening and diagnosis, biology, risk factors, treatments and interventions, services, lifespan issues, or infrastructure and surveillance. We found that funding patterns remained largely consistent during 2017–2019. Biological research received a relative majority of funding (32.59%), followed by treatments and interventions (22.87%). While given higher funding priority by the Interagency Autism Coordinating Committee’s recent budget recommendation, fewer funds were awarded to research areas like services (5.02%) and lifespan issues (2.51%), indicating a misalignment between funding patterns and the Interagency Autism Coordinating Committee budget recommendation. These findings emphasize the need for autism research funding to align with the Interagency Autism Coordinating Committee budget recommendations to best meet the needs of the autism community, particularly autistic younger, middle-aged, and older adults. Lay abstract In 2017, an advisory board consisting of autism researchers and community members recommended that funders of autism research prioritize research projects on: (1) treatments/interventions, (2) evidence-based services, and (3) lifespan issues. To describe funding in these areas since this recommendation was made, we searched the databases of the three largest federal funders of autism research in the United States. We found that the largest portion of federal funding during 2017–2019 was awarded to research on the biology of autism (32.59%) and treatments and interventions for autism (22.87%). Less funds were awarded to research areas that are high funding priorities by the Interagency Autism Coordinating Committee budget recommendation including services (5.02%) and lifespan issues (2.51%). Our findings emphasize that autism research funding is not consistent with the Interagency Autism Coordinating Committee budget recommendation to increase funding particularly to services and lifespan issues. We recommend that funding patterns should shift to better align with these priorities so that autism research may better serve the needs of the autism community.
4
Walz, Bruce J., Richard A. Bissell, Brian Maguire i James A. Judge. "Vaccine Administration by Paramedics: A Model for Bioterrorism and Disaster ResponsePreparation". Prehospital and Disaster Medicine 18, nr 4 (grudzień 2003): 321–26. http://dx.doi.org/10.1017/s1049023x00000558.
Pełny tekst źródłaStreszczenie:
AbstractThe events of 11 September 2001 have had a profound effect on disaster planning efforts in the United States. This is true especially in the area of bioter-rorism. One of the major tenets of bioterrorism response is the vaccination of at-riskpopulations. This paper investigates the efficacy of training emergency medical services paramedics to administer vaccines in public health settings as preparation for and response to bioterrorism events and other disaster events.The concept of vaccination administration by specially trained paramedics is not new. Various programs to provide immunizations for emergency services personnel and at-risk civilian populations have been reported.Vaccination programs by paramedics should follow the guidelines of the National Vaccine Advisory Committee of the Centers for Disease Control and Prevention (CDC). Thispaper compares the seven standards of the CDC guidelines to routine paramedic practice and education. It is concluded that paramedics are adequately trained to administer vaccines. However, specific training and protocols are needed in the areas of administrative paperwork and patient education. A proposed outline for a paramedic-training program is presented.
5
Walz, Bruce J., Richard A. Bissell, Brian Maguire i James A. Judge. "Vaccine Administration by Paramedics: A Model for Bioterrorism and Disaster Response Preparation". Prehospital and Disaster Medicine 18, nr 4 (grudzień 2003): 321–26. http://dx.doi.org/10.1017/s1049023x00001278.
Pełny tekst źródłaStreszczenie:
AbstractThe events of 11 September 2001 have had a profound effect on disaster planning efforts in the United States. This is true especially in the area of bioter-rorism. One of the major tenets of bioterrorism response is the vaccination of at-riskpopulations. This paper investigates the efficacy of training emergency medical services paramedics to administer vaccines in public health settings as preparation for and response to bioterrorism events and other disaster events.The concept of vaccination administration by specially trained paramedics is not new. Various programs to provide immunizations for emergency services personnel and at-risk civilian populations have been reported.Vaccination programs by paramedics should follow the guidelines of the National Vaccine Advisory Committee of the Centers for Disease Control and Prevention (CDC). Thispaper compares the seven standards of the CDC guidelines to routine paramedic practice and education. It is concluded that paramedics are adequately trained to administer vaccines. However, specific training and protocols are needed in the areas of administrative paperwork and patient education. A proposed outline for a paramedic-training program is presented.
6
Stennett, Amanda, Norma Ofsthun, John Larkin, Marta Reviriego-Mendoza, Len Usvyat, Franklin W. Maddux i Jeffrey Hymes. "Treatment of a Large National Population of Anemic Hemodialysis Patients with a Long-Lasting Erythropoietin Stimulating Agent". Blood 128, nr 22 (2.12.2016): 1268. http://dx.doi.org/10.1182/blood.v128.22.1268.1268.
Pełny tekst źródłaStreszczenie:
Abstract Introduction: Patients with chronic kidney disease who progress to end stage renal disease (ESRD) require renal replacement therapy to assume some functions of the diseased kidney and sustain life. Hemodialysis (HD) is the most common option for renal replacement therapy in ESRD patients and includes routine treatments 3 times per week to filter uremic toxins and remove excess fluid from the blood. The prevalence of anemia is high in the ESRD population with about 80% of HD patients being treated with an erythropoietin stimulating agent (ESA) for management of anemia (United States Renal Data System. 2015 USRDS annual data report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2015). Until recently, there had only been a few of choices for ESA therapies in the United States, epoetin alfa, which is considered short-lasting (dosing generally greater than once per week), and darbepoetin alfa, which is middle-lasting (dosing generally once per week). Methoxy polyethylene glycol-epoetin beta is a long lasting ESA (dosing once per 2-4 weeks) that has been recently approved and permitted to be used for treatment of patients with anemia in the United States. At Fresenius Medical Care North America (FMCNA), we began the conversion from use of short- or middle-lasting ESAs to Methoxy polyethylene glycol-epoetin beta in our HD facilities in December of 2014. In this analysis, we aimed to determine the profiles of hemoglobin (Hgb) levels in this large national population of anemic HD patients treated with methoxy polyethylene glycol-epoetin beta. Methods: We retrospectively studied data on HD patients treated at FMCNA facilities that converted from epoetin alfa or darbepoetin alfa to using methoxy polyethylene glycol-epoetin beta for the standard of care treatment of anemia. Data for the weekly Hgb levels that were used to conduct anemia management using the ESAs was analyzed for comparisons. The target goal for ESA treatment at FMCNA is to maintain patient Hgb levels between 10 to 11 g/dL. We computed the 3 months profiles of mean Hgb levels associated with the routine clinical use of methoxy polyethylene glycol-epoetin beta in all (n=118,681) HD patients receiving the long-lasting ESA therapy at FMCNA during May to July of 2016. Additionally, evaluations of mean Hgb levels before and after the conversion to the long-lasting ESA was performed using patient data from September 2014 to July of 2015; this analysis included 24,223, 7,494, and 1,345 anemic HD patients who received methoxy polyethylene glycol-epoetin beta for maintenance of anemia for at least 2, 4 and 6 months, respectively. Results: We found that treatment of anemia in HD patients with methoxy polyethylene glycol-epoetin beta maintained Hgb levels steady at a mean value of 10.7g/dL for the population from May to July of 2016. In an evaluation of Hgb levels before and after the conversion from epoetin alfa or darbepoetin alfa to methoxy polyethylene glycol-epoetin beta, we observed a slight increase of 0.18, 0.17, and 0.15 g/dL in mean Hgb levels after 2, 4, and 6 months of patients receiving the long-lasting ESA for maintenance of anemia (Figures 1-3). There was a slight nadir mean Hgb level of 10.2 g/dL that occurred 1 week prior to conversion to the long-lasting ESA. This was a result of anemia protocols that had patients with higher Hgb values wait until the level had decreased before converting to the long-lasting ESA. Conclusions: The findings of this retrospective investigation indicate that the long-lasting ESA methoxy polyethylene glycol-epoetin beta maintains Hgb levels in target range for HD patients. The conversion from a short- or middle-lasting ESA to the long-lasting ESA methoxy polyethylene glycol-epoetin beta may be associated with overall a minor increase in mean Hgb levels that are on average within normal limits. Disclosures Stennett: Fresenius Medical Care North America: Employment. Ofsthun:Fresenius Medical Care North America: Employment, Equity Ownership. Larkin:Fresenius Medical Care North America: Employment. Reviriego-Mendoza:Fresenius Medical Care North America: Employment. Usvyat:Fresenius Medical Care North America: Employment, Equity Ownership. Maddux:American National Bank & Trust (NASDAQ: AMNB): Membership on an entity's Board of Directors or advisory committees; Fresenius Medical Care North America: Employment, Equity Ownership, Other: Founder: Scholarships Expanding Education 501c3 non profit, Research Funding; Kidney Care Partners: Membership on an entity's Board of Directors or advisory committees; Pacific Renal Care Foundation: Membership on an entity's Board of Directors or advisory committees; Specialty Care: Membership on an entity's Board of Directors or advisory committees; Sound Physicians: Membership on an entity's Board of Directors or advisory committees; Mid Atlantic Renal Coalition: Membership on an entity's Board of Directors or advisory committees. Hymes:Nephroceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Fresenius Medical Care North America: Employment, Equity Ownership.
7
El Rassi, Fuad, John James, Biree Andemariam, Beverley Francis-Gibson, Caterina P. Minniti, Jincy Paulose, Tom Bailey, Olivera Rajkovic-Hooley i Ifeyinwa Osunkwo. "Children in the United States with Sickle Cell Disease Experience Greater Educational Burden Than Those Living in Low/Middle Income and Other High-Income Countries". Blood 138, Supplement 1 (5.11.2021): 3106. http://dx.doi.org/10.1182/blood-2021-146566.
Pełny tekst źródłaStreszczenie:
Abstract Introduction: The Sickle Cell World Assessment Survey (SWAY) was a cross-sectional survey to assess the global impact and treatment of sickle cell disease (SCD). Complications of SCD can lead to significant negative effects on patient (pt) quality of life. Recurrent vaso-occlusive crises (VOCs) are one of the most common SCD complications and can lead to poor quality of life and chronic organ damage. SCD manifestations can start as early as the first year of life. The implications of SCD on a child's life can be far reaching and may affect education, the global impact of which has not been well described. Here, we assess data from SWAY to better understand the impact of SCD on education among pediatric pts in the US vs other high-income countries (HIC) and low/middle-income countries (LMIC). Methods: SWAY included individuals aged ≥6 years with a diagnosis of SCD. The survey was completed by proxy (parent/caregiver/guardian) for pts aged 6-11 years and could be optionally self-completed by pts aged ≥12 years. The survey consisted of 7 ratings-based (Likert scale) questions focused on education, where a score of 5, 6, or 7 indicated increasing levels of agreement. Pediatric pts were defined as those aged <18 years. Per the World Bank definition, HIC were defined as having a gross national income per capita of ≥US$12,536; LMIC represented all remaining countries. SWAY was not designed to assess treatment outcomes; all analyses are descriptive. Age groups were not matched, and pts were not followed up over time. Results: Among the 769 pediatric pts participating in SWAY, there were 77 US respondents to the educational survey (mean age, 12 y), 200 HIC respondents (mean age, 13 y), and 492 LMIC respondents (mean age, 12 y, [one respondent did not provide an age]). Pediatric pts in all groups reported that SCD adversely impacted their education. Of the US respondents, 51%, 45%, and 52% agreed that SCD negatively impacted performance on school tests, overall performance at school, and school attendance, respectively. This was a higher rate of agreement for these statements than that reported by pediatric pts from other HIC (25%, 23%, 36%) and LMIC (37%, 41%, 50%). The US respondents also agreed that SCD negatively affected performance on homework (45%), caused them to repeat a year or class (42%), lowered interest in school (36%), and limited educational progression (35%). Again, this was a higher rate of agreement than that reported by pediatric pts from other HIC (26%, 14%, 19%, 20%) and LMIC (37%, 32%, 34%, 29%). Interestingly, the largest differences in reported school impact occurred between the US and HIC, where the US respondents showed nearly two-fold higher agreement for all statements except for reduced attendance. Conversely, there were only minor differences between respondents from the US and LMIC. Full results are presented in the Figure. Conclusions: A higher proportion of pediatric pts in the US reported a negative impact of SCD on schooling compared with those in HIC and LMIC. These results were unexpected but align strongly with the emerging evidence that social determinants prevalent in the US lends itself away from the benefits of living in a resource-rich nation. Figure 1 Figure 1. Disclosures James: GBT: Honoraria; Novartis: Honoraria. Francis-Gibson: Global Alliance of SCD Organizations: Membership on an entity's Board of Directors or advisory committees; Sickle Cell Disease Association of America: Current Employment; Alliance for Regenerative Medicine Foundation for Cell and Gene Medicine: Membership on an entity's Board of Directors or advisory committees; ASH: Membership on an entity's Board of Directors or advisory committees; Global Blood Therapeutics: Membership on an entity's Board of Directors or advisory committees. Minniti: GBT: Consultancy, Research Funding; Novartis: Consultancy, Honoraria; NovoNordisk: Consultancy, Honoraria; Roche: Consultancy, Honoraria. Paulose: Novartis Pharmaceuticals Corporation: Current Employment. Bailey: Novartis Pharmaceuticals: Other: I am an employee of Adelphi Real World, which received payment from Novartis Pharmaceuticals for this research. Rajkovic-Hooley: Novartis Pharmaceuticals: Other: I am an employee of Adelphi Real World, which received payment from Novartis Pharmaceuticals for this research. Osunkwo: Forma Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Health and Services Administration: Research Funding; Patient Centered Outcomes Research Instituted: Research Funding; Micella Biopharma: Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Chiesi: Consultancy; Emmaus: Consultancy; Cyclerion: Consultancy; Acceleron: Consultancy; Global Blood Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Terumo: Consultancy.
8
Andrade-Gonzalez, Xavier, Anuhya Kommalapati, Allison M. Bock, Jacqueline Wang, Antoine Saliba, Javier Munoz, David J. Inwards i in. "Influence of Treatment Facility Type and Annual Patient Volume on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis". Blood 138, Supplement 1 (5.11.2021): 1348. http://dx.doi.org/10.1182/blood-2021-151888.
Pełny tekst źródłaStreszczenie:
Abstract Introduction: Mantle cell lymphoma (MCL) is an uncommon hematological malignancy with an estimated incidence of 1 per 100,000 persons per year in the United States and represents only about 5% of all non-Hodgkin lymphomas. Several studies have shown that treatment at academic centers and a higher hospital case volume are associated with improved outcomes for uncommon hematological malignancies, probably due to increased provider expertise and access to novel therapies. Treatment of MCL can be complex given the heterogenous nature of the disease and a frequent need for autologous stem cell transplantation in eligible patients. However, the impact of treatment at an academic center and facility patient volume on the survival of patients with MCL has not been well studied in large cohorts. In this study, we utilized the National Cancer Database (NCDB) to investigate the impact of treatment at an academic center and treatment facility volume on the overall survival (OS) of patients with MCL. Methods: The NCDB was used to identify adult patients (≥ 18 years) with newly diagnosed MCL from 2004 through 2017. For facility patient volume analysis, patients were divided into groups based on the average number of new MCL patients seen annually: Tercile 1 [T1] (1-3 patients/year), Tercile 2 [T2] (4-5 patients/year) and Tercile 3 [T3] (≥6 patients/year). Treating centers were divided into Academic and Non-academic using the NCDB definitions. Academic centers were defined as centers that accessions more than 500 newly diagnosed cancer cases per year, participate in postgraduate medical education in at least four program areas including internal medicine and surgery and participates in cancer-related clinical trials. The primary endpoint was overall survival (OS). Survival analysis was performed using the Kaplan-Meier method and Cox hazards proportional model. Statistical analysis was performed using SPSS version 25. Results: We identified 22,752 patients with MCL during the study period. 9,484 (42%) patients were treated at academic centers and 13,070 (57%) were treated at non-academic centers. In terms of facility patient volume 10,948 patients (48%) were in the T1 group, 4,637 (20%) were in the T2 group and 7,166 (31%) were in the T3 group. No significant differences were found in baseline demographics (age, gender, race/ethnicity, comorbidity scores), socioeconomical variables (insurance type, median income, area of residence) and disease-related factors (B-symptoms, Ann Arbor stage) between patients treated academic vs nonacademic centers, or between patients in T1 vs T2 vs T3 groups. Notably, compared to lower volume facilities, T3 facilities were more likely to be academic centers (T3: 81% vs T2: 42% vs T1: 16%, p<0.001) . After a median follow-up of 3.4 years, the median overall survival (OS) was 5.6 years for the entire cohort. The median OS was inferior for patients treated at lower volume facilities (4.1 years for T1, 5.1 years for T2 and 9.0 years for T3, p<0.001) (Figure 1A). Similarly, the median OS was shorter for patients treated at non-academic centers vs academic centers (4.3 years vs 7.5 years respectively, p<0.001) (Figure 1B). In a multivariate analysis, treatment at a lower patient volume facility (Hazard ratio [HR] Q1= 1.26 [95%CI = 1.18-1.34]) and treatment at a non-academic center (HR = 1.1, 95%CI = 1.01-1.12) were both independent prognostic factors of inferior OS, after adjusting for demographics (age, gender, ethnicity, area of residence) and socioeconomic variables (income and insurance status). Conclusion: Patients with MCL treated at academic and higher volume facilities had a higher OS compared to patients treated at non-academic and lower volume facilities.. Additional research is needed to fully understand the mechanisms behind these differences. Patients with MCL may benefit from an early referral to academic and high-volume centers. Figure 1 Figure 1. Disclosures Munoz: Merck: Research Funding; Portola: Research Funding; Genentech: Research Funding; Incyte: Research Funding; Janssen: Research Funding; Seattle Genetics: Research Funding; Pharmacyclics/Abbvie, Bayer, Gilead/Kite Pharma, Pfizer, Janssen, Juno/Celgene, BMS, Kyowa, Alexion, Beigene, Fosunkite, Innovent, Seattle Genetics, Debiopharm, Karyopharm, Genmab, ADC Therapeutics, Epizyme, Beigene, Servier: Consultancy; Gilead/Kite Pharma, Kyowa, Bayer, Pharmacyclics/Janssen, Seattle Genetics, Acrotech/Aurobindo, Beigene, Verastem, AstraZeneca, Celgene/BMS, Genentech/Roche.: Speakers Bureau; Millennium: Research Funding; Pharmacyclics: Research Funding; Celgene: Research Funding; Physicians' Education Resource: Honoraria; Gilead/Kite Pharma: Research Funding; Kyowa: Honoraria; Bayer: Research Funding; Seattle Genetics: Honoraria; OncView: Honoraria; Targeted Oncology: Honoraria. Paludo: Karyopharm: Research Funding. Habermann: Seagen: Other: Data Monitoring Committee; Incyte: Other: Scientific Advisory Board; Tess Therapeutics: Other: Data Monitoring Committee; Morphosys: Other: Scientific Advisory Board; Loxo Oncology: Other: Scientific Advisory Board; Eli Lilly & Co.,: Other: Scientific Advisor. Nowakowski: Daiichi Sankyo: Consultancy; Zai Labolatory: Consultancy; TG Therapeutics: Consultancy; Blueprint Medicines: Consultancy; Nanostrings: Research Funding; MorphoSys: Consultancy; Kymera Therapeutics: Consultancy; Incyte: Consultancy; Ryvu Therapeutics: Consultancy; Kyte Pharma: Consultancy; Genentech: Consultancy, Research Funding; Roche: Consultancy, Research Funding; Celgene/Bristol Myers Squibb: Consultancy, Research Funding; Selvita: Consultancy; Curis: Consultancy; Karyopharm Therapeutics: Consultancy; Bantham Pharmaceutical: Consultancy. Wang: Novartis: Research Funding; LOXO Oncology: Membership on an entity's Board of Directors or advisory committees, Research Funding; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Genentech: Research Funding; Eli Lilly: Membership on an entity's Board of Directors or advisory committees; MorphoSys: Research Funding; InnoCare: Research Funding; Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding.
9
Srivastava, Amit, i Justine Alderfer. "2721. US States’ Policies for Meningococcal Vaccination vs. Disease Epidemiology". Open Forum Infectious Diseases 6, Supplement_2 (październik 2019): S957—S958. http://dx.doi.org/10.1093/ofid/ofz360.2398.
Pełny tekst źródłaStreszczenie:
Abstract Background Serogroup B (MenB) is the leading cause of invasive meningococcal disease (IMD) cases in the United States, including 69% of cases among 16- to 23-year-olds. College students have 3.5 times greater MenB risk vs noncollege individuals, and MenB caused all college IMD outbreaks between 2011 and 2019. For healthy adolescents, the Advisory Committee on Immunization Practices (ACIP) recommends routine MenACWY vaccination at 11 and 16 years and MenB vaccination based on individual clinical decision-making, preferably at 16‒18 years (Figure 1A, B). Given the recent shift in disease epidemiology, we investigated whether current state policies also shifted to help protect adolescents against all 5 meningococcal serogroups. Methods We researched requirements for meningococcal vaccination using state public health websites and national stakeholder materials (e.g., Immunization Action Coalition and their state chapters). Data as of November 2018 were compiled by vaccine type, age, and school/college requirements. Results Forty-five states and Washington DC require either meningococcal vaccination and/or vaccine education for school attendance (grades 6–12) and for college attendance. Thirty-one states require a MenACWY primary dose (at 11 years), of which 16 states also require the booster dose at 16 years (Table 1, Figure 1C). One state requires MenB vaccination at 16–18 years. Of the 8 states that experienced college MenB outbreaks between 2013 and February 2019, all require vaccination or education for MenACWY but not MenB (Table 2). These differences in state requirements may underlie the reported adolescent vaccination coverage rates for MenACWY (85% for ≥ 1 dose, 44% for ≥ 2 doses) and MenB (14.5% for ≥ 1 dose of multidose series) vaccines, and additional reasons may be the efficiency of school-based vaccination programs, strength of the 11-year immunization platform, the more recent availability of MenB vs MenACWY vaccines, and disparate ACIP recommendations for these vaccines. Conclusion State vaccination requirements have helped catalyze MenACWY vaccine impact. Tailoring new requirements to the current epidemiology can help quell MenB disease and ensure that US adolescents are fully protected against meningococcal disease. Funding: Pfizer Disclosures All authors: No reported disclosures.
10
Hood, Anna M., Heather Strong, Cara Nwankwo, Yolanda Johnson, Constance A. Mara, Lisa M. Shook, William Brinkman i in. "Addressing Recruitment Challenges in the Engage-HU Trial in Young Children with Sickle Cell Disease". Blood 136, Supplement 1 (5.11.2020): 26–27. http://dx.doi.org/10.1182/blood-2020-141471.
Pełny tekst źródłaStreszczenie:
Background: Sickle cell disease (SCD) is a genetic disorder that causes significant medical and neurologic morbidity in children. Hydroxyurea (HU) is the primary medication used to prevent these complications. National Heart, Lung, and Blood Institute (NHLBI) guidelines recommend offering HU to children as young as 9 months of age with SCD (HbSS or HbSB0 thalassemia) using a shared decision-making approach. Although HU has proven efficacious it remains underutilized and caregivers report that they are not always actively involved in the decision to initiate this therapy. Reasons for limited HU uptake likely include lack of clinician knowledge and training and negative caregiver perceptions. Thus, we developed the Engage-HU trial as a novel approach to address HU utilization barriers. A critical consideration for this trial was that SCD primarily affects individuals of African and Hispanic/Latino descent. In these minority populations, intervention trials are sometimes terminated early because of recruitment difficulties related to mistrust of research, caregiver burden, and transportation issues. As such, the Engage-HU trial design included best-practice strategies for recruiting people of color in research. This study describes these strategies, the initial recruitment plan, preliminary recruitment outcomes and strategies, and our procedural adaptations. Study Design and Methods: Engage-HU is a randomized control trial (NCT03442114) to assess how clinicians can engage caregivers in a shared discussion that considers their values and preferences and includes evidence that supports HU. Engage-HU compares two dissemination methods for clinicians to facilitate shared decision-making with caregivers of young children with SCD: 1) the American Society of Hematology Pocket Guide, and 2) the HU Shared-Decision Making (H-SDM) Toolkit. The study aims to recruit 174 caregivers and evaluate the effectiveness of the dissemination methods on patient-centered outcomes (caregiver confidence in decision-making and perceptions of experiencing shared decision-making) as well as HU uptake and child health outcomes. Eligible children are aged 0 to 5 years, candidates for HU, and their caregiver has not made a decision about HU in the past 3 months. The trial is being conducted at 9 sites in the United States and uses a stepped-wedge design. Data will be analyzed based on the intent-to-treat principle. All participants will remain in the arm of the study to which they were randomized, regardless of whether or not they receive the assigned dissemination method. The primary endpoints are caregiver decisional uncertainty and caregiver perception of shared decision-making measured using validated tools. Data will be analyzed using a linear mixed effects regression model with a robust variance estimator and maximum likelihood estimation with observations clustered within site. The Engage-HU trial includes adaptations to increase recruitment such as tailored messaging, a relational recruitment approach, streamlined data collection, and a Stakeholder Advisory Committee. However, even with these adaptations, the first 6-months of the trial yielded lower than anticipated recruitment. Rather than terminate the trial or accept low enrollment, the research team implemented a series of recruitment strategies to address barriers including helping to improve research coordinator knowledge of the study purpose and adjusting no-show and follow-up procedures (e.g., calls to families after missed appointments and reminder calls before appointments). Site clinicians and clinic staff were provided with additional training so they could give more context about Engage-HU to caregivers and the study principal investigator led monthly "all coordinator" calls to provide support by sharing updates and experiences about successful recruitment. Implementation of these strategies resulted in triple the number of enrollments over the next 7-months compared to the previous 6-months (Table 1). Our goal in sharing this information is to provide lessons learned that can be implemented in future trials with the systematically underserved SCD population. It is also anticipated that methods described here may also inform clinical approaches to better engage caregivers of young children around critical clinical conversations, such as initiating medications like HU. Disclosures King: Magenta Therapeutics: Membership on an entity's Board of Directors or advisory committees; Bioline: Consultancy; RiverVest: Consultancy; Novimmune: Research Funding; Celgene: Consultancy; Tioma Therapuetics: Consultancy; Amphivena Therapeutics: Research Funding; WUGEN: Current equity holder in private company; Cell Works: Consultancy; Incyte: Consultancy. Smith-Whitley:Prime: Other: Education material; Celgene: Membership on an entity's Board of Directors or advisory committees; Global Blood Therapeutics: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Neumayr:Emmaus: Consultancy; Bayer: Consultancy; CTD Holdings: Consultancy; Pfizer: Consultancy; ApoPharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Micelle: Other: Site principal investigator; GBT: Other: Site principal investigator; PCORI: Other: site principal investigator; Novartis: Other: co-investigator; Bluebird Bio: Other: co-investigator; Sangamo Therapeutics: Other; Silarus: Other; Celgene: Other; La Jolla Pharmaceuticals: Other; Forma: Other; Imara: Other; National Heart, Lung, and Blood Institute: Other; Health Resources and Services Administration: Other; Centers for Disease Control and Prevention: Other; Seattle Children's Research: Other. Yates:Novartis: Research Funding. Thompson:Novartis: Consultancy, Honoraria, Research Funding; CRISPR/Vertex: Research Funding; BMS: Consultancy, Research Funding; Baxalta: Research Funding; Biomarin: Research Funding; bluebird bio, Inc.: Consultancy, Research Funding.
Rozprawy doktorskie na temat "United States. National Advisory Committee on Education"
1
Haus, David R. "Expertise at war the National Committee on Education by Radio, the National Association of Broadcasters, the Federal Radio Commission and the battle for American radio /". Connect to this title online, 2006. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=bgsu1151521658.
Pełny tekst źródła
2
Haus, David Russell Jr. "EXPERTISE AT WAR: THE NATIONAL COMMITTEE ON EDUCATION BY RADIO, THE NATIONAL ASSOCIATION OF BROADCASTERS, THE FEDERAL RADIO COMMISSION AND THE BATTLE FOR AMERICAN RADIO". Bowling Green State University / OhioLINK, 2006. http://rave.ohiolink.edu/etdc/view?acc_num=bgsu1151521658.
Pełny tekst źródła
3
Patail, Shoaib Chotoo. "Implications of a national immunization registry an alliance to win the race for the future care and accuracy of pediatric immunization". CSUSB ScholarWorks, 2004. https://scholarworks.lib.csusb.edu/etd-project/2600.
Pełny tekst źródłaStreszczenie:
This project examines the role of immunization registries and their effect on a health care delivery system. Recent efforts to attain coverage of child populations by recommended vaccines have included initiatives by federal and state agencies, as well as private foundations, to develop and implement statewide community-based childhood immunization registries.
Książki na temat "United States. National Advisory Committee on Education"
1
United States. Congress. House. Committee on Education and Labor. Subcommittee on Health and Safety. Oversight on the two advisory committees to OSHA: The National Advisory Committee on Occupational Safety and Health, and the Advisory Committee on Construction Safety and Health : hearing before the Subcommittee on Health and Safety of the Committee on Education and Labor, House of Representatives, One Hundredth Congress, second session, hearing held in Washington, DC, June 15, 1988. Washington: U.S. G.P.O., 1988.
Znajdź pełny tekst źródła
2
President's Homeland Security Advisory Council (U.S.). Quadrennial Review Advisory Committee final report. Washington, D.C.]: U.S. Dept. of Homeland Security, Homeland Security Advisory Council, 2010.
Znajdź pełny tekst źródła
3
Roland, Alex. Model research: The National Advisory Committee for Aeronautics, 1915-1958. Washington, D.C: Scientific and Technical Information Branch, National Aeronautics and Space Administration, 1985.
Znajdź pełny tekst źródła
4
Roland, Alex. Model research: The National Advisory Committee for Aeronautics, 1915-1958. Washington, D.C: Scientific and Technical Information Branch, National Aeronautics and Space Administration, 1985.
Znajdź pełny tekst źródła
5
Committee, United States President's National Security Telecommunications Advisory. The President's National Security Telecommunications Advisory Committee (NSTAC): 15th anniversary, 1982-1997. [Washington, D.C.?: The Committee, 1997.
Znajdź pełny tekst źródła
6
United States. President's National Security Telecommunications Advisory Committee. The President's National Security Telecommunications Advisory Committee (NSTAC): 15th anniversary, 1982-1997. [Washington, D.C.?: The Committee, 1997.
Znajdź pełny tekst źródła
7
United States. President's National Security Telecommunications Advisory Committee. The President's National Security Telecommunications Advisory Committee (NSTAC): 15th anniversary, 1982-1997. [Washington, D.C.?: The Committee, 1997.
Znajdź pełny tekst źródła
8
United States. Dept. of Defense. Graduate Medical Education Advisory Committee. Final report of the Department of Defense, Graduate Medical Education Advisory Committee. [Washington, D.C.?: Dept. of Defense, 1987.
Znajdź pełny tekst źródła
9
W, Gray George. Frontiers of flight: The story of NACA research. New York: A.A. Knopf, 1988.
Znajdź pełny tekst źródła
10
United States. Veterans Administration. Department of Medicine and Surgery. VA Voluntary Service National Advisory Committee: Representative and deputy representative handbook. Washington, DC: Veterans Administration, Department of Medicine and Surgery, 1985.
Znajdź pełny tekst źródłaCzęści książek na temat "United States. National Advisory Committee on Education"
1
Mccaffrey, David P., i David W. Hart. "The Social Benefits and Risks of Entrepreneurs and Free Agents". W Wall Street Polices Itself, 25–41. Oxford University PressNew York, NY, 1998. http://dx.doi.org/10.1093/oso/9780195111873.003.0002.
Pełny tekst źródłaStreszczenie:
Abstract How effectively the securities industry operates affects economic well being in the United States. Corporations rely on the industry to raise much of the capital allowing them to survive and expand, although, since the early 1980s, securities markets have been more important as centers for trading and sources of short-term financing than as sources for new long-term capital (Advisory Committee on the Capital Formation and Regulatory Processes, 1996: Appendix A, Figure 1). Customers are willing to invest in manufacturing and other industries because they are not locked in to decisions; they can liquidate their investments using the secondary markets such as stock exchanges and the over-the-counter (OTC) market. Governments could not operate without a market for governmental debt, and elected officials are sensitive to what financial markets’ vitality implies for national welfare. Certain defining episodes in U.S. history involved the securities markets, such as the frantic market speculation and manipulations in the 1920s, the Depression in the 1930s, and most recently (and probably less lastingly) the “greedy” 1980s. Today, technological changes play out vividly in these markets. We exaggerate only moderately when speaking of a “borderless” world economy in which financial transactions reflect economic changes in multiple nations in ways governments find difficult to regulate.
2
Gauthier, Anne Hèléne. "Introduction". W The State and the Family, 1–12. Oxford University PressOxford, 1996. http://dx.doi.org/10.1093/oso/9780198288046.003.0001.
Pełny tekst źródłaStreszczenie:
Abstract Since the tum of the century, the family in industrialized countries has undergone major transformations. Family size has declined, marriage has become less popular, unions are increasingly unstable, and women are no longer assuming their traditional role of housewives. At the same time, governments ‘ policies in respect of families have also greatly changed and expanded. Initially limited to mothers ‘ and children ‘s protection, governments ‘ policies have been steadily expanded to cover other aspects of family life and a larger number of families, as well as to provide a higher level of support. As a result, what is often referred to today as family policy encompasses a large number of measures and benefits ranging from measures specifically targeted at working parents, lone-parent families, or low-income families, to those more generally designed to support all families with children. It is the trends over time in these measures and their inter-country variations which are analysed in this book. The task is an ambitious one: a period of study covering a whole century, a comparison between twenty-two countries, and an analysis of the interplay between demographic changes and family policy. The story is however a fascinating one. What is now called family policy has changed considerably over the past 100 years, revealing major similarities in the ways governments have viewed and supported families, as well as revealing major dissimilarities shaped by country-specific events, ideologies, and circumstances. Until recently, the term ‘family policy ‘ had been very little used in political and academic circles. Alva Myrdal, in Sweden, talked of ‘a programme for family security ‘ in 1939, and a German article published in 1958 used in its title the term ‘Familienpolitik ‘ (Wuermeling, et al. 1958). During these early years, references to family policy or to governmental programmes for families were however mainly confined to restricted circles. The situation changed substantially from the mid-1960s. For example, the Swedish government set up a Family Policy Committee in 1965, the Austrian government set up a Family Policy Advisory Council in 1967, while suggestions for the adoption of a national family policy were made in the United States during a series of hearings on the family in 1973 (Kamerman and Kahn, 1978).
Streszczenia konferencji na temat "United States. National Advisory Committee on Education"
1
Berman, Ronald, i Cathy Ames. "Private Online Workspaces for Doctoral Learners - Enhanced Communication and Reduced Isolation". W InSITE 2015: Informing Science + IT Education Conferences: USA. Informing Science Institute, 2015. http://dx.doi.org/10.28945/2182.
Pełny tekst źródłaStreszczenie:
This quantitative exploratory study, a continuation of the university’s four year research initiative that addresses the high national rate of doctoral student attrition, investigates whether a private online workspace for doctoral students and their dissertation committee will enhance communication and reduce learner’s feelings of isolation during the dissertation phase. Private doctoral workspaces provide a virtual platform for learner and committee collaboration, manuscript review, and milestone planning. The purpose of this study is to offer preliminary feedback to guide in the further development of the virtual workspace. To assess effectiveness of the private doctoral workspace, a seven question online survey was created to address usage, communication, and isolation. Two surveys were distributed to 803 doctoral candidates at a private southwestern university in the United States, resulting in 328 respondents for the first survey, and 190 respondents for the second survey. Doctoral learners completed the survey at the onset of the private doctoral workspace implementation, and again four months later. The results indicate that doctoral learners regularly access their private dissertation workspace, communicate more frequently with their dissertation committee, and have reduced feelings of isolation. These results may provide similar benefits to other academic groups working together on long-term projects in other disciplines.
2
Peck, Roxy. "Developing statistical reasoning in a “piecemeal” secondary statistics curriculum—the next step". W Next Steps in Statistics Education. IASE international Association for Statistical Education, 2009. http://dx.doi.org/10.52041/srap.09103.
Pełny tekst źródłaStreszczenie:
In the last decade, statistics and data analysis have become a more visible component of the secondary school mathematics curriculum in the United States. In most cases, statistics and data analysis topics have been divided up and spread through the mathematics curriculum. However, many important concepts of statistics are not mathematical in nature and are not easily integrated into existing mathematics courses. As a consequence, most students complete their secondary education having seen a number of graphical and numerical statistical methods but having not encountered many key concepts required for mature statistical reasoning. Recognizing that the addition of a separate statistics course to the secondary curriculum is unlikely, an alternate approach is proposed. With support from the American Statistical Association (ASA) and the ASA/NCTM (National Council of Teachers of Mathematics) Joint Committee on Probability and Statistics in the K-12 Curriculum, a capstone experience for secondary students has been designed. Making Sense of Statistical Studies is a coordinated and coherent set of case studies that can be integrated into mathematics courses to provide students with an understanding of the data analysis process and help them develop the conceptual understanding that provides the foundation for statistical reasoning. This paper contributes to the conference topic of curricular materials and tools for improving students’ learning at school level.
3
Hoyt, John G. "Dr. Daniel Savitsky". W SNAME Chesapeake Power Boat Symposium. SNAME, 2010. http://dx.doi.org/10.5957/cpbs-2010-008.
Pełny tekst źródłaStreszczenie:
Dr. Daniel Savitsky, Professor Emeritus Stevens Institute of Technology, has been a leader in the field of high-speed marine vehicle hydrodynamics for 70 years. His landmark paper, "Hydrodynamic Design of Planing Hulls", published in the very first (1964) edition of the Society of Naval Architects and Marine Engineers Marine Technology, is well known to all in the field. An in-depth look at his life and career beyond this singular contribution will be shared in honor of his many contributions to his family, colleagues, students and friends. Dan Savitsky began his career as a student at the College of the City of New York, graduating in 1942 to work for the EDO Corporation at College Point, New York. Here at EDO, his love for the planing surface was born with his involvement in the development of seaplane floats during the war. After being drafted into the Army of the United States, he was assigned to the National Advisory Committee for Aeronautics’ Langley Laboratory in 1944, where he advanced his knowledge not only of planing surfaces, but an important future skill, model testing. His next and current home was Stevens Institute’s Davidson Laboratory, where he obtained a Masters degree in 1952 and up the ranks from project engineer to Director of the Laboratory. He later obtained his Doctorate from New York University in 1972, and mentored untold scores of students. He achieved many honors during this time such as the SNAME Cochrane and Davidson awards and the Stevens Jess Davis award. These awards were earned through scientific contributions passed on to us in numerous papers and presentations, as well as through his active participation in professional organizations such as SNAME, ASME, ATTC, ITTC and many more. There are numerous accounts of his kindness and concern as well as scholarly advice to laymen, students and professionals alike. An attempt is made here to present Dr Savitsky’s many contributions, not just a tabulation of his technical achievements, but to include his influence on the many who have worked with or were taught by him.
Raporty organizacyjne na temat "United States. National Advisory Committee on Education"
1
Anderson, Donald M., Lorraine C. Backer, Keith Bouma-Gregson, Holly A. Bowers, V. Monica Bricelj, Lesley D’Anglada, Jonathan Deeds i in. Harmful Algal Research & Response: A National Environmental Science Strategy (HARRNESS), 2024-2034. Woods Hole Oceanographic Institution, lipiec 2024. http://dx.doi.org/10.1575/1912/69773.
Pełny tekst źródłaStreszczenie:
Harmful and toxic algal blooms (HABs) are a well-established and severe threat to human health, economies, and marine and freshwater ecosystems on all coasts of the United States and its inland waters. HABs can comprise microalgae, cyanobacteria, and macroalgae (seaweeds). Their impacts, intensity, and geographic range have increased over past decades due to both human-induced and natural changes. In this report, HABs refers to both marine algal and freshwater cyanobacterial events. This Harmful Algal Research and Response: A National Environmental Science Strategy (HARRNESS) 2024-2034 plan builds on major accomplishments from past efforts, provides a state of the science update since the previous decadal HARRNESS plan (2005-2015), identifies key information gaps, and presents forward-thinking solutions. Major achievements on many fronts since the last HARRNESS are detailed in this report. They include improved understanding of bloom dynamics of large-scale regional HABs such as those of Pseudo-nitzschia on the west coast, Alexandrium on the east coast, Karenia brevis on the west Florida shelf, and Microcystis in Lake Erie, and advances in HAB sensor technology, allowing deployment on fixed and mobile platforms for long-term, continuous, remote HAB cell and toxin observations. New HABs and impacts have emerged. Freshwater HABs now occur in many inland waterways and their public health impacts through drinking and recreational water contamination have been characterized and new monitoring efforts have been initiated. Freshwater HAB toxins are finding their way into marine environments and contaminating seafood with unknown consequences. Blooms of Dinophysis spp., which can cause diarrhetic shellfish poisoning, have appeared around the US coast, but the causes are not understood. Similarly, blooms of fish- and shellfish-killing HABs are occurring in many regions and are especially threatening to aquaculture. The science, management, and decision-making necessary to manage the threat of HABs continue to involve a multidisciplinary group of scientists, managers, and agencies at various levels. The initial HARRNESS framework and the resulting National HAB Committee (NHC) have proven effective means to coordinate the academic, management, and stakeholder communities interested in national HAB issues and provide these entities with a collective voice, in part through this updated HARRNESS report. Congress and the Executive Branch have supported most of the advances achieved under HARRNESS (2005-2015) and continue to make HABs a priority. Congress has reauthorized the Harmful Algal Bloom and Hypoxia Research and Control Act (HABHRCA) multiple times and continues to authorize the National Oceanic and Atmospheric Administration (NOAA) to fund and conduct HAB research and response, has given new roles to the US Environmental Protection Agency (EPA), and required an Interagency Working Group on HABHRCA (IWG HABHRCA). These efforts have been instrumental in coordinating HAB responses by federal and state agencies. Initial appropriations for NOAA HAB research and response decreased after 2005, but have increased substantially in the last few years, leading to many advances in HAB management in marine coastal and Great Lakes regions. With no specific funding for HABs, the US EPA has provided funding to states through existing laws, such as the Clean Water Act, Safe Drinking Water Act, and to members of the Great Lakes Interagency Task Force through the Great Lakes Restoration Initiative, to assist states and tribes in addressing issues related to HAB toxins and hypoxia. The US EPA has also worked towards fulfilling its mandate by providing tools and resources to states, territories, and local governments to help manage HABs and cyanotoxins, to effectively communicate the risks of cyanotoxins and to assist public water systems and water managers to manage HABs. These tools and resources include documents to assist with adopting recommended recreational criteria and/or swimming advisories, recommendations for public water systems to choose to apply health advisories for cyanotoxins, risk communication templates, videos and toolkits, monitoring guidance, and drinking water treatment optimization documents. Beginning in 2018, Congress has directed the U.S. Army Corps of Engineers (USACE) to develop a HAB research initiative to deliver scalable HAB prevention, detection, and management technologies intended to reduce the frequency and severity of HAB impacts to our Nation’s freshwater resources. Since the initial HARRNESS report, other federal agencies have become increasingly engaged in addressing HABs, a trend likely to continue given the evolution of regulations(e.g., US EPA drinking water health advisories and recreational water quality criteria for two cyanotoxins), and new understanding of risks associated with freshwater HABs. The NSF/NIEHS Oceans and Human Health Program has contributed substantially to our understanding of HABs. The US Geological Survey, Centers for Disease Control and Prevention, and the National Aeronautics Space Administration also contribute to HAB-related activities. In the preparation of this report, input was sought early on from a wide range of stakeholders, including participants from academia, industry, and government. The aim of this interdisciplinary effort is to provide summary information that will guide future research and management of HABs and inform policy development at the agency and congressional levels. As a result of this information gathering effort, four major HAB focus/programmatic areas were identified: 1) Observing systems, modeling, and forecasting; 2) Detection and ecological impacts, including genetics and bloom ecology; 3) HAB management including prevention, control, and mitigation, and 4) Human dimensions, including public health, socio-economics, outreach, and education. Focus groups were tasked with addressing a) our current understanding based on advances since HARRNESS 2005-2015, b) identification of critical information gaps and opportunities, and c) proposed recommendations for the future. The vision statement for HARRNESS 2024-2034 has been updated, as follows: “Over the next decade, in the context of global climate change projections, HARRNESS will define the magnitude, scope, and diversity of the HAB problem in US marine, brackish and freshwaters; strengthen coordination among agencies, stakeholders, and partners; advance the development of effective research and management solutions; and build resilience to address the broad range of US HAB problems impacting vulnerable communities and ecosystems.” This will guide federal, state, local and tribal agencies and nations, researchers, industry, and other organizations over the next decade to collectively work to address HAB problems in the United States.